Angelo D. Favia
Eli Lilly (United States)(US)
Publications by Year
Research Areas
Inflammatory Bowel Disease, Microscopic Colitis, Computational Drug Discovery Methods, Eosinophilic Esophagitis, Protein Structure and Dynamics
Most-Cited Works
- → Protein promiscuity and its implications for biotechnology(2009)496 cited
- → The SDR (short-chain dehydrogenase/reductase and related enzymes) nomenclature initiative(2008)390 cited
- → Design, Synthesis, and 3D QSAR of Novel Potent and Selective Aromatase Inhibitors(2004)122 cited
- → Multitarget Drug Discovery for Alzheimer's Disease: Triazinones as BACE‐1 and GSK‐3β Inhibitors(2014)122 cited
- → The role of fragment-based and computational methods in polypharmacology(2011)117 cited
- → Structural Insights into Monoamine Oxidase Inhibitory Potency and Selectivity of 7-Substituted Coumarins from Ligand- and Target-Based Approaches(2006)107 cited
- → Deciphering Cryptic Binding Sites on Proteins by Mixed-Solvent Molecular Dynamics(2017)93 cited
- → Design, Synthesis, and Biological Evaluation of Imidazolyl Derivatives of 4,7-Disubstituted Coumarins as Aromatase Inhibitors Selective over 17-α-Hydroxylase/C17−20 Lyase(2011)89 cited
- → Three‐dimensional model of the human aromatase enzyme and density functional parameterization of the iron‐containing protoporphyrin IX for a molecular dynamics study of heme‐cysteinato cytochromes(2006)85 cited
- → Identification and Characterization of Carprofen as a Multitarget Fatty Acid Amide Hydrolase/Cyclooxygenase Inhibitor(2012)81 cited